Arvinas

Arvinas is a clinical-stage biotechnology company based in New Haven, Connecticut, founded in 2013 by Dr. Craig Crews. The company specializes in developing PROTAC® (Proteolysis-Targeting Chimera) therapeutics, a new class of drugs aimed at degrading disease-causing proteins. This innovative approach targets previously "undruggable" proteins, particularly in oncology and neurodegenerative diseases, by utilizing the cell's natural protein degradation mechanisms. Arvinas is advancing several promising candidates in its pipeline, including ARV-471, which targets the estrogen receptor for breast cancer and is currently in Phase 3 trials, and ARV-110, aimed at the androgen receptor for prostate cancer, in Phase 2 trials. The company collaborates with major biopharmaceutical firms like Pfizer and Bayer to enhance its research and development efforts. Arvinas is committed to cultivating new treatments through targeted protein degradation, emphasizing scientific rigor and collaboration to bring innovative therapies to patients with life-threatening diseases.